Trial intelligence / Profile preview

Phase II Weekly Non-pegylated Liposomal Doxorubicin in Metastatic Gastric Carcinoma (Second-line)

2009-017151-97Phase 2Completed

Sponsor: Centro di Riferimento Oncologico di Aviano
Start: May 2010
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of doxorubicin in gastric carcinoma (GC), sponsored by Centro di Riferimento Oncologico di Aviano. Primary endpoint: Objective response rate. Started May 2010; status: completed.

Drugs

doxorubicin

Conditions

gastric carcinoma (GC)

Beyond the preview

Go deeper on 2009-017151-97.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-017151-97.